Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Files Avastin sBLA For Relapsed Metastatic Colorectal Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

The application would expand on an October labeling change which added third-line data.

You may also be interested in...



Genentech Halts Enrollment In Avastin Early-Stage Colon Cancer Trial

The firm reports a higher rate of non-colon cancer related deaths in the AVANT trial for adjuvant use of bevacizumab.

Genentech Halts Enrollment In Avastin Early-Stage Colon Cancer Trial

The firm reports a higher rate of non-colon cancer related deaths in the AVANT trial for adjuvant use of bevacizumab.

Genentech Avastin Label Adds Third-Line Data Showing Minimal Efficacy

NCI study of bevacizumab demonstrated a 1% response rate in refractory metastatic colorectal cancer when combined with 5-FU/LV.

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel